Antiarthritic properties and unique pharmacologic profile of a potential chrysotherapeutic agent: S K & F D-30162. 1976

D T Walz, and M J DiMartino, and L W Chakrin, and B M Sutton, and A MISHER

SK&F D-39162, a potential chrysotherapeutic agent, on oral administration was effective in suppressing the development of inflammatory lesions and 7S anti-sheep red blood cell antibody formation in adjuvant arthritic rats. Oral absorption of SK&F D-39162 was indicated by the presence of serum gold levels. In contrast to orally administered SK&F D-39162, gold sodium thiomalate administered intramuscularly at equivalent gold doses, appeared to be less effective in suppressing the primary and secondary lesions of adjuvant arthritis, produced relatively higher levels of gold in both serum and kidneys and produced marked toxicity. Other pharmacologic properties of SK&F D-39162 distinguishing it from gold sodium thiomalate which may have clinical significance include potent inhibitory activity on antibody-forming cells, immediate hypersensitivity reactions and extracellular release of lysosomal enzymes. In further contrast to gold sodium thiomalate, SK&F D-39162 is not a potent inhibitor of sulfhydryl group reactivity. In pharmacokinetic studies, the daily oral administration of SK&F D-39162 to normal rats produced greater stability of blood gold levels and less kidney gold accumulation than parenterally administered gold sodium thiomalate.

UI MeSH Term Description Entries
D006969 Hypersensitivity, Immediate Hypersensitivity reactions which occur within minutes of exposure to challenging antigen due to the release of histamine which follows the antigen-antibody reaction and causes smooth muscle contraction and increased vascular permeability. Atopic Hypersensitivity,Hypersensitivity, Atopic,Hypersensitivity, Type I,IgE-Mediated Hypersensitivity,Type I Hypersensitivity,Atopic Hypersensitivities,Hypersensitivities, Atopic,Hypersensitivities, IgE-Mediated,Hypersensitivities, Immediate,Hypersensitivities, Type I,Hypersensitivity, IgE-Mediated,IgE Mediated Hypersensitivity,IgE-Mediated Hypersensitivities,Immediate Hypersensitivities,Immediate Hypersensitivity,Type I Hypersensitivities
D008247 Lysosomes A class of morphologically heterogeneous cytoplasmic particles in animal and plant tissues characterized by their content of hydrolytic enzymes and the structure-linked latency of these enzymes. The intracellular functions of lysosomes depend on their lytic potential. The single unit membrane of the lysosome acts as a barrier between the enzymes enclosed in the lysosome and the external substrate. The activity of the enzymes contained in lysosomes is limited or nil unless the vesicle in which they are enclosed is ruptured or undergoes MEMBRANE FUSION. (From Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed). Autolysosome,Autolysosomes,Lysosome
D008297 Male Males
D010720 Phosphines Inorganic or organic compounds derived from phosphine (PH3) by the replacement of H atoms. (From Grant & Hackh's Chemical Dictionary, 5th ed)
D011714 Pyrans Pyran
D006046 Gold A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
D006051 Aurothioglucose A thioglucose derivative used as an antirheumatic and experimentally to produce obesity in animals. Gold Thioglucose,Aureotan,Auromyose,Aurothioglucose, Sodium Salt, beta-D Isomer,Aurothioglucose, beta-D Isomer,Gold-50,Solganal,Solganal B Oleosum,Solganol,Thioglucosoaurate,Aurothioglucose, beta D Isomer,B Oleosum, Solganal,Gold 50,Gold50,Oleosum, Solganal B,Thioglucose, Gold,beta-D Isomer Aurothioglucose
D006462 Hemolytic Plaque Technique A method to identify and enumerate cells that are synthesizing ANTIBODIES against ANTIGENS or HAPTENS conjugated to sheep RED BLOOD CELLS. The sheep red blood cells surrounding cells secreting antibody are lysed by added COMPLEMENT producing a clear zone of HEMOLYSIS. (From Illustrated Dictionary of Immunology, 3rd ed) Jerne's Plaque Technique,Hemolytic Plaque Technic,Jerne's Plaque Technic,Hemolytic Plaque Technics,Hemolytic Plaque Techniques,Jerne Plaque Technic,Jerne Plaque Technique,Jernes Plaque Technic,Jernes Plaque Technique,Plaque Technic, Hemolytic,Plaque Technic, Jerne's,Plaque Technics, Hemolytic,Plaque Technique, Hemolytic,Plaque Technique, Jerne's,Plaque Techniques, Hemolytic,Technic, Hemolytic Plaque,Technic, Jerne's Plaque,Technics, Hemolytic Plaque,Technique, Hemolytic Plaque,Technique, Jerne's Plaque,Techniques, Hemolytic Plaque
D006632 Histamine An amine derived by enzymatic decarboxylation of HISTIDINE. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. Ceplene,Histamine Dihydrochloride,Histamine Hydrochloride,Peremin
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

D T Walz, and M J DiMartino, and L W Chakrin, and B M Sutton, and A MISHER
February 1984, Seminars in arthritis and rheumatism,
D T Walz, and M J DiMartino, and L W Chakrin, and B M Sutton, and A MISHER
June 1986, Clinical pharmacy,
D T Walz, and M J DiMartino, and L W Chakrin, and B M Sutton, and A MISHER
November 1992, The Journal of rheumatology. Supplement,
D T Walz, and M J DiMartino, and L W Chakrin, and B M Sutton, and A MISHER
January 1994, The American journal of cardiology,
D T Walz, and M J DiMartino, and L W Chakrin, and B M Sutton, and A MISHER
January 1984, Clinical pharmacy,
D T Walz, and M J DiMartino, and L W Chakrin, and B M Sutton, and A MISHER
January 1993, Agents and actions. Supplements,
D T Walz, and M J DiMartino, and L W Chakrin, and B M Sutton, and A MISHER
December 1982, Cancer treatment reviews,
D T Walz, and M J DiMartino, and L W Chakrin, and B M Sutton, and A MISHER
November 2011, Physical review letters,
D T Walz, and M J DiMartino, and L W Chakrin, and B M Sutton, and A MISHER
September 1992, Agents and actions,
D T Walz, and M J DiMartino, and L W Chakrin, and B M Sutton, and A MISHER
March 1973, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!